Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
A member of our team will contact you to confirm availability and finalize your appointment
FAQs Frequently asked questions The FDA does not currently approve the BPC-157 peptide for medical use
Drug Metab Dispos
A favorable FDA final determination is required before any compounding pharmacy can legally dispense BPC-157 to patients
Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
